Education
About Us
Working with TipRanks
Follow Us
Brainsway Ltd (BWAY)
NASDAQ:BWAY
BWAY Stock Chart & Stats
$23.18
-$0.11(-1.13%)
At close: 4:00 PM EST
$23.18
-$0.11(-1.13%)
Day’s Range― - ―
52-Week Range$7.84 - $24.84
Previous CloseN/A
Volume9.67K
Average Volume (3M)93.77K
Market Cap
$456.83M
Enterprise Value$222.68M
Total Cash (Recent Filing)$70.46M
Total Debt (Recent Filing)$6.75M
Price to Earnings (P/E)69.5
Beta1.41
Next Earnings
Mar 11, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding19,585,468
10 Day Avg. Volume156,868
30 Day Avg. Volume93,772
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)2.57
Price to Sales (P/S)3.90
P/FCF Ratio24.63
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue4.54
Enterprise Value/Gross Profit6.05
Enterprise Value/Ebitda24.43
Forecast
1Y Price Target
$22.00Price Target Upside-5.09% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.27
Revenue Forecast (FY)$64.14M
Bulls Say, Bears Say
Bulls Say
Product InnovationDeep TMS 360 represents a major technological upgrade that delivers more uniform brain stimulation, which can improve clinical consistency and increase clinician interest in adopting the system.
Regulatory ExpansionFDA label expansion to cover adolescents aged 15 to 21 with major depressive disorder expands the addressable patient population and supports higher clinic demand for Deep TMS services.
Strategic Investments And Revenue VisibilityMinority equity investments in mental health service providers and existing multi-year contracts with material remaining performance obligations provide clearer revenue visibility and create additional channels for Deep TMS adoption.
Bears Say
Adoption RiskSlower-than-projected uptake of Deep TMS systems could limit equipment sales and constrain overall revenue growth if clinical adoption lags expectations.
Financing And Dilution RiskThe potential need for additional capital raises could lead to long-term equity dilution, which would pressure shareholder value if external funding is required to support growth initiatives.
Reimbursement And Market Access RiskFailure to expand reimbursement coverage and pay-per-use acceptance may restrict patient access and reduce service-based revenue potential for Deep TMS treatments.
Brainsway News
BWAY FAQ
What was Brainsway Ltd’s price range in the past 12 months?
Brainsway Ltd lowest stock price was $7.84 and its highest was $24.84 in the past 12 months.
What is Brainsway Ltd’s market cap?
Brainsway Ltd’s market cap is $456.83M.
When is Brainsway Ltd’s upcoming earnings report date?
Brainsway Ltd’s upcoming earnings report date is Mar 11, 2026 which is in 50 days.
How were Brainsway Ltd’s earnings last quarter?
Brainsway Ltd released its earnings results on Nov 11, 2025. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.047 by -$0.007.
Is Brainsway Ltd overvalued?
According to Wall Street analysts Brainsway Ltd’s price is currently Overvalued.
Does Brainsway Ltd pay dividends?
Brainsway Ltd does not currently pay dividends.
What is Brainsway Ltd’s EPS estimate?
Brainsway Ltd’s EPS estimate is 0.05.
How many shares outstanding does Brainsway Ltd have?
Brainsway Ltd has 19,585,468 shares outstanding.
What happened to Brainsway Ltd’s price movement after its last earnings report?
Brainsway Ltd reported an EPS of $0.04 in its last earnings report, missing expectations of $0.047. Following the earnings report the stock price went down -5.831%.
Which hedge fund is a major shareholder of Brainsway Ltd?
Currently, no hedge funds are holding shares in BWAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Brainsway Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (-5.09% Downside)
$22.00 (-5.09% Downside)
Blogger Sentiment
Bullish
BWAY Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 199.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 16.6%
Last 30 Days ▲ 16.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
124.61%
12-Months-Change
Fundamentals
Return on Equity
11.05%
Trailing 12-Months
Asset Growth
56.81%
Trailing 12-Months
Company Description
Brainsway Ltd
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
BWAY Company Deck
BWAY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
BrainsWay's Q3 2025 earnings call indicated strong growth and positive developments, including record revenue, increased system shipments, and successful strategic investments. Despite increased operating expenses and a delay in FDA clearance for Neurolief, the company's performance and raised guidance reflect a generally optimistic outlook.View all BWAY earnings summariesBWAY Stock 12 Month Forecast
Average Price Target
$22.00
▼(-5.09% Downside)
Technical Analysis
Sanuwave Health
―
Tactile Systems Technology
―
Viemed Healthcare
―
TriSalus Life Sciences
―
NeuroPace
―
Ownership Overview
―
Insiders
0.89% Mutual Funds
19.85% Other Institutional Investors
78.52% Public Companies and
Individual Investors